Firebrick Pharma (ASX:FRE) Announces Nasodine Throat Spray Launch

In a recent ASX announcement, Firebrick Pharma Limited (ASX:FRE) has confirmed the Firebrick Pharma Nasodine Throat Spray Launch, marking a strategic expansion of the company’s povidone-iodine product portfolio. This represents the first new addition to the Nasodine range since the successful introduction of Nasodine Nasal Spray in Singapore this year. The company has secured TGA export approval (permit #517465) and partnered with Australian manufacturer Probiotec for initial production, with the first batch expected to be available for export in November 2025.

The Singapore market will serve as the launch territory in December 2025, leveraging established distribution networks and regulatory pathways. This development demonstrates Firebrick’s ability to execute its commercialisation strategy efficiently, building upon proven market entry approaches whilst expanding its therapeutic applications within the antiseptic category.

What Makes the Nasodine Throat Spray Different from Traditional Gargle Products?

The Nasodine Throat Spray delivers a 1.0% povidone-iodine formulation specifically designed to address limitations of conventional throat gargle products. The compact 25mL bottle features an integrated precision nozzle that targets affected throat areas directly, eliminating the inconvenience and potential staining associated with traditional gargle formats.

Key product specifications include:

• Active ingredient of 1.0% povidone-iodine antiseptic
• Compact 25mL bottle with precision spray nozzle
• No expectoration required after application
• Pleasant-tasting formulation for improved patient compliance
• Direct delivery method to affected areas

The throat spray format addresses a clear market gap, particularly in Australia. Whilst Betadine-branded throat sprays exist in Singapore and other markets, this povidone-iodine delivery method is not currently available in Australia. This positions Firebrick to capture market share in regions where convenient spray formats are preferred over traditional gargles, particularly amongst consumers seeking ease-of-use solutions.

How Does Povidone-Iodine Work as an Antiseptic for Throat Infections?

Povidone-iodine (PVP-I) is a broad-spectrum antiseptic that effectively eliminates bacteria, viruses, and fungi upon contact with affected tissues. The 1.0% concentration provides antimicrobial protection whilst offering immediate relief for sore throat symptoms, making it suitable for both treatment and prevention of throat infections.

For investors, povidone-iodine’s proven efficacy profile represents a low-risk product development strategy. The compound has decades of clinical validation and regulatory acceptance, reducing approval hurdles and accelerating market entry compared to novel pharmaceutical compounds requiring extensive clinical trials. This established safety profile minimises development risk whilst maximising commercial potential.

When Will the Firebrick Pharma Nasodine Throat Spray Launch Occur in Singapore?

The Firebrick Pharma Nasodine Throat Spray Launch will occur in two distinct phases beginning December 2025. The initial phase targets healthcare professionals and hospitals, leveraging Innorini Life Sciences’ established medical networks to build clinical adoption and professional recommendations before expanding into retail channels.

Singapore Launch Timeline:

This hospital-first approach mirrors the successful launch strategy used for Nasodine Nasal Spray, building clinical credibility before expanding into retail channels. This methodology reduces marketing costs whilst establishing professional endorsement for consumer adoption.

Why Did Firebrick Select Probiotec as a Manufacturing Partner?

Firebrick has already placed an order for production of an initial batch with its Australian manufacturing partner, Probiotec. This partnership provides established manufacturing scalability and quality assurance capabilities essential for pharmaceutical product commercialisation. The relationship enables Firebrick to focus on product development and market expansion whilst leveraging Probiotec’s expertise.

The Australian manufacturing base offers several strategic advantages, including proximity to management oversight, established regulatory compliance, and simplified supply chain management. Manufacturing in Australia also enables access to TGA export permits, facilitating international market entry. Product is expected to be released and available for export during November 2025.

What Distribution Strategy Will Support the Launch?

Firebrick’s market entry strategy leverages its established Singapore operations and proven regulatory pathway for antiseptic products. The company’s partnership with Innorini Life Sciences provides immediate access to healthcare professional networks and distribution infrastructure developed through previous Nasodine Nasal Spray commercialisation efforts.

The licensing partner expects marketing of the throat spray to start in December 2025, focused on Singapore hospitals and doctors. They anticipate the product will be available in retail channels around mid-2026, following the proven commercialisation pathway established by the nasal spray. This sequential approach balances rapid market entry with sustainable distribution development.

How Does This Launch Position Firebrick in the Antiseptic Market?

The Firebrick Pharma Nasodine Throat Spray Launch demonstrates successful execution of the company’s core strategy to develop multiple povidone-iodine formulations targeting different therapeutic applications. This investor update validates the company’s ability to leverage existing regulatory approvals and manufacturing partnerships to accelerate new product development.

Strategic Investment Advantages:

• Proven Market Validation: Success in Singapore with the nasal spray provides a blueprint for throat spray adoption.
• Established Manufacturing: The Probiotec manufacturing partnership enables production scaling as demand grows.
• Regulatory Efficiency: The antiseptic classification avoids lengthy and costly pharmaceutical approval processes.

With a market capitalisation of approximately $16.1 million and a reported cash position from its latest quarterly filings, the company appears positioned to fund this next phase of commercialisation. This launch is a significant step in diversifying its revenue streams and strengthening its position in the global antiseptic market, offering a clear growth narrative for current and prospective shareholders.

Want more ASX news?

Want to stay informed on significant ASX biotechnology announcements like Firebrick Pharma’s latest developments? Join over 20,000 investors who receive StockWire X’s Big News Blasts—a free email service delivering major company announcements directly to subscribers’ inboxes, complete with comprehensive analysis. This service ensures investors never miss important market-moving news across non-resource sectors including biotechnology, technology, healthcare, finance, and industrials. Subscribe to Big News Blasts today to receive instant alerts on announcements that matter most.